A compelling receptor profile is not enough.
Telesti applies exposure-linked pharmacology, integrated safety and candidate-development discipline to next-generation neuroplastogens.
Preserve relevant biology. Improve the development profile.
Neuroplasticity may support durable changes in CNS function, but the usefulness of a medicine depends on more than biological activity. Telesti is evaluating compounds designed to combine relevant serotonergic pharmacology with an exposure, safety and developability profile suitable for practical clinical use.
Our approach does not assume that receptor bias, cell-based plasticity or rodent behavior predicts a particular human experience. Those questions require controlled human evaluation.
Every workstream answers a decision.
Functional pharmacology
Matched assay systems, reference ligands and mechanistic controls are used to determine what the molecule does—not merely where it binds. Functional selectivity remains a preclinical hypothesis until linked to human outcomes.
Exposure-linked translation
Unbound plasma and brain exposure, PK/PD and metabolite coverage anchor the interpretation of behavior, efficacy and safety. Nominal dose alone is insufficient.
Human-effect uncertainty
Preclinical behavioral assays, including head-twitch response, can inform candidate selection but cannot establish whether a compound is non-hallucinogenic or non-impairing in humans.
Integrated safety
Functional 5-HT2B activity, hERG and other ion channels, in-vivo telemetry and systemic safety are separate liabilities that require an integrated, exposure-based assessment.
Developability
Process chemistry, solid form, formulation, analytical control, stability and tox-to-clinical comparability determine whether a promising molecule can become a reliable clinical product.
Preclinical behavior is evidence for a candidate decision—not proof of a human perceptual claim.
Advance, redesign or stop.
Each tranche of work should resolve a defined risk before the next capital-intensive stage begins. The goal is not to accumulate studies; it is to make progressively stronger candidate decisions.
Truth
Identity, reproducibility and prospective criteria.
Series
Pharmacology and major liability separation.
Exposure
Unbound CNS exposure and tractable metabolism.
Translation
Reproducible signal separated from impairment and safety risk.
Candidate
One development candidate plus a distinct backup.
See where the work stands.
The public pipeline shows current stage and the next objective checkpoint without publishing proprietary structures, thresholds or unpublished data.